HIF1A and myocardial infarction: In conclusion, the present study indicated that TXL therapy may dose-dependently improve the cardiac function and ameliorate ventricular remodeling after MI by inducing angiogenesis and neovascularization via enhancing the phosphorylation of Akt and ERK, expression and activity of HIF-1α, and the protein level of VEGF and p-eNOS.